Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: Opevesostat
DRUG: Olaparib
DRUG: Docetaxel
DRUG: Cabazitaxel
DRUG: Fludrocortisone acetate
DRUG: Dexamethasone
DRUG: Prednisone

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]